Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors - 14/11/13
Abstract |
Background |
The possible connection between psoriasis with cardiovascular disease and associated risk factors has been implied, but inconsistent results have been reported.
Objective |
We sought to create an overview and statistical summary of the previous literature with elucidating subgroup analysis.
Methods |
This was a meta-analysis of observational studies using random effect statistics. A systematic search of observational studies of psoriasis as study variable and cardiovascular disease and associated risk factors as outcome, published before October 25, 2012, was conducted.
Results |
Of 835 references in the original search, 75 relevant articles were identified. We included 503,686 cases and 29,686,694 controls. Psoriasis was associated with cardiovascular disease in total (odds ratio [OR] 1.4; 95% confidence interval [CI] 1.2-1.7), ischemic heart disease (OR 1.5; 95% CI 1.2-1.9), peripheral vascular disease (OR 1.5; 95% CI 1.2-1.8), atherosclerosis (OR 1.1; 95% CI 1.1-1.2), diabetes (OR 1.9; 95% CI 1.5-2.5), hypertension (OR 1.8; 95% CI 1.6-2.0), dyslipidemia (OR 1.5; 95% CI 1.4-1.7), obesity by body mass index (OR 1.8; 95% CI 1.4-2.2), obesity by abdominal fat (OR 1.6; 95% CI 1.2-2.3), and the metabolic syndrome (OR 1.8; 95% CI 1.2-2.8), but not associated with cerebrovascular disease (OR 1.1; 95% CI 0.9-1.3) and cardiovascular mortality (OR 0.9; 95% CI 0.4-2.2). The strongest associations were seen in hospital-based studies and psoriatic arthritis. Population-based studies did not show significant associations, with the exception of dyslipidemia.
Limitations |
The heterogeneity of the studies makes clinical interpretation challenging.
Conclusions |
In aggregate, psoriasis was associated with ischemic heart disease and cardiovascular risk factors. The association was only significant for hospital-based studies, except for dyslipidemia, which was also significant in population-based studies.
Le texte complet de cet article est disponible en PDF.Key words : cardiovascular disease, diabetes mellitus, hypercholesterolemia, hypertension, inflammation, meta-analysis, obesity, plaque, psoriasis
Plan
Cofinanced with grants by the Danish Agency for Science, Technology, and Innovation and LEO Pharma A/S (Dr Miller). |
|
Disclosure: Dr Miller is cofinanced by LEO Pharma A/S. Dr Jemec reports receiving consulting fees from Abbott Laboratories, Astra-Zeneca, Coloplast, MSD, Novartis, Pfizer, and Dumex-Alpharma; lecture fees from Abbott Laboratories, Galderma, Pfizer, and Roche; grant support from Abbott Laboratories, Pfizer, Photocure, and LEO Pharma; equipment on loan from Michelson Diagnostics; and reimbursement for travel expenses from Abbott Laboratories, Galderma, and Photocure. Drs Ellervik, and Yazdanyar have no conflicts of interest to declare. |
Vol 69 - N° 6
P. 1014-1024 - décembre 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?